Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

379 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, van Laere S, Dirix L, Sweep FC, Span PN, Linn SC, Foekens JA, Sleijfer S, Berns EM, Jansen MP. Ramirez-Ardila DE, et al. Among authors: sleijfer s. Breast Cancer Res Treat. 2013 May;139(1):39-49. doi: 10.1007/s10549-013-2529-7. Epub 2013 Apr 17. Breast Cancer Res Treat. 2013. PMID: 23592373
Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Helleman J, Sleijfer S, Klijn JG, Foekens JA, Berns EM. Jansen MP, et al. Among authors: sleijfer s. Breast Cancer Res Treat. 2009 Jul;116(2):263-71. doi: 10.1007/s10549-008-0125-z. Epub 2008 Jul 16. Breast Cancer Res Treat. 2009. PMID: 18629630
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, Hogendoorn PC, Verweij J, Blay JY. Sleijfer S, et al. Eur J Cancer. 2010 Jan;46(1):72-83. doi: 10.1016/j.ejca.2009.09.022. Eur J Cancer. 2010. PMID: 19853437
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, Smid M, Brinkman A, den Dekker AT, Leroy IM, van Ijcken WF, Sleijfer S, Foekens JA, Dorssers LC. van Agthoven T, et al. Among authors: sleijfer s. Br J Cancer. 2009 Dec 1;101(11):1824-32. doi: 10.1038/sj.bjc.6605423. Epub 2009 Nov 10. Br J Cancer. 2009. PMID: 19904269 Free PMC article.
379 results